Sign In
Buy MNPR
$60.56
-0.700 (-1.14%)
At Close: Jun 03, 2026
Monopar Announces Camsirubicin Clinical Program Update - Improved Side Effect Profile Seen to Date Compared to Doxorubicin
12:00pm, Tuesday, 14'th Feb 2023 GlobeNewswire Inc.
WILMETTE, Ill., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to ext
Monopar Announces Projected Timeline of Upcoming Q1 2023 Data Events for Validive, Camsirubicin, and MNPR-101 RIT
12:00pm, Thursday, 26'th Jan 2023 GlobeNewswire Inc.
WILMETTE, Ill., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to ext
Benzinga's Top Ratings Upgrades, Downgrades For January 23, 2023
03:00pm, Monday, 23'rd Jan 2023 Benzinga
Upgrades
For ONE Gas Inc (NYSE:OGS), Guggenheim upgraded the previous rating of Sell to Neutral. For the third quarter, ONE Gas had an EPS of $0.44, compared to year-ago quarter EPS of $0.38. The stoc
Monopar Announces Successful Advancement of Camsirubicin Phase 1b Clinical Trial Past Fourth Cohort, Escalates Next to 650mg/m2
12:00pm, Wednesday, 18'th Jan 2023 GlobeNewswire Inc.
WILMETTE, Ill., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to exte
Monopar Announces Promising MNPR-202 Data from Ongoing National University of Singapore Collaboration
12:00pm, Monday, 12'th Dec 2022 GlobeNewswire Inc.
WILMETTE, Ill, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to exte
Monopar Therapeutics (MNPR) Up On Soft Tissue Sarcoma Study Data
06:10pm, Friday, 18'th Nov 2022 Zacks Investment Research
Monopar Therapeutics (MNPR) surges after it reports data from its ongoing phase Ib dose escalation study evaluating camsirubicin for treating soft-tissue sarcoma.
Monopar Therapeutics (MNPR) Up On Soft Tissue Sarcoma Study Data
03:11pm, Friday, 18'th Nov 2022
Monopar Therapeutics (MNPR) surges after it reports data from its ongoing phase Ib dose escalation study evaluating camsirubicin for treating soft-tissue sarcoma.
Monopar Therapeutics Inc. (MNPR) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
02:55pm, Friday, 18'th Nov 2022 Zacks Investment Research
Monopar Therapeutics Inc. (MNPR) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revision
Why Apyx Medical Shares Dipped Over 60%; Here Are 123 Biggest Movers From Yesterday
10:10am, Friday, 11'th Nov 2022 Benzinga
Gainers
Fast Radius, Inc. (NASDAQ: FSRD) shares jumped 156.2% to close at $0.2608 on Thursday after dipping 40% on Wednesday. Fast Radius received Bankruptcy court approval of first day motions relat
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
10:00am, Tuesday, 08'th Nov 2022 Benzinga
Gainers
Digital World Acquisition Corp. (NASDAQ: DWAC) shares jumped 66.5% to settle at $29.10 on Monday amid recent reports suggesting Donald Trump could announce a 2024 presidential run this week.
Why Sonnet BioTherapeutics Shares Surged Over 66%; Here Are 63 Biggest Movers From Yesterday
07:31am, Tuesday, 01'st Nov 2022 Benzinga
Gainers
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) climbed 66.4% to close at $1.93 on Monday after the company announced an agreement with Janssen for the evaluation of three Sonnet product
Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202
12:00pm, Thursday, 27'th Oct 2022 GlobeNewswire Inc.
WILMETTE, Ill., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to ext
Monopar Announces Presentation Selected for 2022 Connective Tissue Oncology Society (CTOS) Annual Meeting
12:00pm, Wednesday, 12'th Oct 2022 GlobeNewswire Inc.
WILMETTE, Ill., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to ext
Dow falls 300 points after best start to a quarter since 1938
03:28pm, Wednesday, 05'th Oct 2022 MarketWatch
U.S. stocks trade lower on Wednesday as a more cautious tone prevailed following a strong start to the fourth quarter.
Monopar's stock gains 13% after completing enrollment for an experimental therapy for cancer patients
08:50am, Wednesday, 05'th Oct 2022
Shares of Monopar Therapeutics Inc. MNPR, +6.92% gained 13.5% in premarket trading on Wednesday after the company said it completed enrollment in a Phase 2b clinical trial evaluating its experimental
